Pricing
  1. US-listed companies
  2. U.S. Stem Cell, Inc.
  3. Financials
  4. Selling, general & administrative

U.S. Stem Cell, Inc.【USRM】

Market cap
$64.15K
P/E ratio
SummaryFinancials
Period EndSelling, general & administrative (Million USD)YoY (%)
Dec 31, 20222-22.14%
Dec 31, 20212-12.58%
Dec 31, 20203-54.01%
Dec 31, 20186+28.37%
Dec 31, 20174+35.62%
Dec 31, 20163-14.30%
Dec 31, 20154-18.43%
Dec 31, 20145-88.06%
Dec 31, 201339+6.16%
Dec 31, 201237+6.29%
Dec 31, 201135

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)